Immunotherapy Clinical Trial Reveals Brain Tumor Shrinkage, Continues with Phase 3 Study – Markets Insider
|
Immunotherapy Clinical Trial Reveals Brain Tumor Shrinkage, Continues with Phase 3 Study
Markets Insider SUMMIT, N.J., April 25, 2018 /PRNewswire/ — Following successful Phase 1 clinical trials, the Toca regimen – a new immunotherapy for patients with recurrent brain cancer – has advanced to a Phase 3 study, which is currently underway. The trial is … |
